<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02393963</url>
  </required_header>
  <id_info>
    <org_study_id>B2013-089</org_study_id>
    <nct_id>NCT02393963</nct_id>
  </id_info>
  <brief_title>Intra-articular Tranexamic Acid in the Reduction of Blood Transfusions in Primary Total Hip and Total Knee Arthroplasty</brief_title>
  <official_title>Role of Low Dose Intra-articular Tranexamic Acid in the Reduction of Blood Transfusions in Primary Total Hip and Total Knee Arthroplasty: A Randomized Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orthopaedic Innovation Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orthopaedic Innovation Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blinded, controlled trial in patients undergoing elective Total
      Knee Arthroplasty (TKA) and Total Hip Arthroplasty (THA). The study group will receive
      intra-articular Tranexamic Acid (TXA) while the control group will receive normal saline
      placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this study is to determine if intra-articular administration of low
      dose TXA following THA and TKA results in a clinically relevant reduction in blood loss. The
      secondary purpose is to determine if there is an increased risk of thromboembolic phenomena
      with the use of TXA following elective THA and TKA. The primary outcome metric will be - drop
      in hemoglobin following surgery; secondary metrics include blood loss, transfusion rate,
      d-dimers, troponin levels, symptomatic deep venous thrombosis (DVT) and pulmonary embolism
      (PE), vascular events (myocardial infarction, stroke), major and minor bleeding, and death.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">December 21, 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in hemoglobin during hospital stay</measure>
    <time_frame>routinely measured post-op day 1 and 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Troponin</measure>
    <time_frame>Every 6 hours for 24 hours post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer</measure>
    <time_frame>Post-op day 1 and 2</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Post-operative blood transfusion</measure>
    <time_frame>During the first 7 days</time_frame>
    <description>documentation of blood transfusion post-operative</description>
  </other_outcome>
  <other_outcome>
    <measure>Major or minor bleeding events</measure>
    <time_frame>within 90 days of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Self-reported visual disturbances</measure>
    <time_frame>within 90 days of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Self-reported symptomatic DVT</measure>
    <time_frame>within 90 days of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Self-reported PE</measure>
    <time_frame>within 90 days of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Self-reported stroke</measure>
    <time_frame>within 90 days of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Death</measure>
    <time_frame>within 90 days of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Intra-operative fluid balance</measure>
    <time_frame>during surgery</time_frame>
    <description>documentation of the volume of saline fluid via intravenous given to patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Bleeding sources other than the knee or hip (eg: GI bleed)</measure>
    <time_frame>within 90 days of surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>post-operative fluid balance</measure>
    <time_frame>within 3- 5 days of surgery</time_frame>
    <description>documentation of the volume of saline fluid via intravenous given to patients</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-articular administration of low dose Tranexamic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium Chloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>0.5g Tranexamic Acid in 0.9% Sodium Chloride (study group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.</description>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <other_name>DIN#: 02246365, Sandoz Canada Inc.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% Sodium Chloride (placebo group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sodium Chloride solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  with osteoarthritis

          -  scheduled for elective primary unilateral THR or TKR

          -  provided informed consent

          -  can read, write and speak English

        Exclusion Criteria:

          -  history of arterial or venous thromboembolic disease (myocardial infarction,
             symptomatic ischemic heart disease, atrial fibrillation, cerebrovascular accident,
             deep-vein thrombosis, pulmonary embolus, or thrombogenic cardiac valvular disease or
             rhythm disease)

          -  pre-operative Hg of &lt;120 g/L

          -  Known allergy to Tranexamic Acid

          -  Coagulation disorder

          -  Acquired disturbances of color vision

          -  Hepatic insufficiency, any history of liver disease

          -  Renal insufficiency (on dialysis)

          -  Preoperative prophylactic use of antiplatelet or anticoagulant therapy such as
             Clopidogrel, Warfarin, dabigatran or Rivaroxaban. This does not include low dose
             Aspirin (81mg)

          -  Patients with a history of subarachnoid hemorrhage [20]

          -  Simultaneous bilateral THA or TKA

          -  Any contra-indication for spinal anesthesia

          -  Allergy to Celecoxib, which will be the only nonsteroidal anti-inflammatory drugs
             (NSAID) used in the multi-modal analgesia regime.

          -  Retinal vein or retinal artery occlusion

          -  Female on oral contraceptive pills and/or premenopausal

          -  Concurrently taking hydrochlorothiazide, desmopressin, sulbactam-ampicillin,
             carbazochrome, ranitidine and/or nitroglycerin for the duration of the surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas R Turgeon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Concordia Joint Replacement Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Concordia Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2K 3S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2015</study_first_submitted>
  <study_first_submitted_qc>March 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

